Negative regulation of FOXP3 expression by c-Rel O-GlcNAcylation.
NF-kappaB
Treg cells
autoimmunity
transcription
type 1 diabetes
Journal
Glycobiology
ISSN: 1460-2423
Titre abrégé: Glycobiology
Pays: England
ID NLM: 9104124
Informations de publication
Date de publication:
07 08 2021
07 08 2021
Historique:
received:
28
02
2020
revised:
17
12
2020
accepted:
17
12
2020
pubmed:
15
1
2021
medline:
1
4
2022
entrez:
14
1
2021
Statut:
ppublish
Résumé
O-GlcNAcylation is a reversible post-translational protein modification that regulates fundamental cellular processes including immune responses and autoimmunity. Previously, we showed that hyperglycemia increases O-GlcNAcylation of the transcription factor, nuclear factor kappaB c-Rel at serine residue 350 and enhances the transcription of the c-Rel-dependent proautoimmune cytokines interleukin-2, interferon gamma and granulocyte macrophage colony stimulating factor in T cells. c-Rel also plays a critical role in the transcriptional regulation of forkhead box P3 (FOXP3)-the master transcription factor that governs development and function of Treg cells. Here we show that the regulatory effect of c-Rel O-GlcNAcylation is gene-dependent, and in contrast to its role in enhancing the expression of proautoimmune cytokines, it suppresses the expression of FOXP3. Hyperglycemia-induced O-GlcNAcylation-dependent suppression of FOXP3 expression was found in vivo in two mouse models of autoimmune diabetes; streptozotocin-induced diabetes and spontaneous diabetes in nonobese diabetic mice. Mechanistically, we show that both hyperglycemia-induced and chemically enhanced cellular O-GlcNAcylation decreases c-Rel binding at the FOXP3 promoter and negatively regulates FOXP3 expression. Mutation of the O-GlcNAcylation site in c-Rel, (serine 350 to alanine), augments T cell receptor-induced FOXP3 expression and resists the O-GlcNAcylation-dependent repression of FOXP3 expression. This study reveals c-Rel S350 O-GlcNAcylation as a novel molecular mechanism inversely regulating immunosuppressive FOXP3 expression and proautoimmune gene expression in autoimmune diabetes with potential therapeutic implications.
Identifiants
pubmed: 33442719
pii: 6090127
doi: 10.1093/glycob/cwab001
pmc: PMC8351495
doi:
Substances chimiques
Forkhead Transcription Factors
0
Foxp3 protein, mouse
0
Proto-Oncogene Proteins c-rel
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-826Subventions
Organisme : NIAMS NIH HHS
ID : T32AR007569
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY033002
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY022938
Pays : United States
Organisme : NEI NIH HHS
ID : T32 EY007157
Pays : United States
Organisme : BLRD VA
ID : IK6 BX003604
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI144264
Pays : United States
Organisme : NEI NIH HHS
ID : T32EY007157
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK128463
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007569
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA246194
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.